The drug pricing reforms enacted by the Inflation Reduction Act are casting a long shadow over the drug development sector as 2023 begins.
It isn’t that drug development will necessarily be crushed by the new law. Just that things are likely to change...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?